Covidien:
|
|
|
|
|
|
|
|
|
WHO:
|
|
|
|
|
|
Jeffrey Saver, MD
|
|
|
|
|
|
|
|
SWIFT, Lead Author
|
|
|
|
|
|
|
|
Professor of Neurology and Director
|
|
|
|
|
|
|
|
UCLA Stroke Center, David Geffen School of Medicine
|
|
|
|
|
|
|
|
University of California, Los Angeles
|
|
|
|
|
|
|
|
|
|
WHAT:
|
|
|
|
|
|
Results from the Solitaire with the Intention for Thrombectomy
(SWIFT) Study will be announced at a press conference at 8AM CT –
followed by a late breaking trial presentation at 12 PM CT. The
Solitaire™ FR Revascularization Device is a stent-based mechanical
thrombectomy system from Covidien. It combines the ability to
revascularize and retrieve the clot in a single device. The device
is designed to be passed through the obstruction and deployed,
thereby offering the potential for flow restoration and the ability
to retrieve clots in patients experiencing acute ischemic stroke.
The objective of the SWIFT study is to demonstrate substantial
equivalence in the safety and effectiveness of the Solitaire™ FR
Revascularization Device when compared to the MERCI® Retrieval.
|
|
|
|
|
|
|
|
|
|
WHERE:
|
|
|
|
|
|
International Stroke Conference
|
|
|
|
|
|
|
|
Ernest N. Morial Convention Center
|
|
|
|
|
|
|
|
- Press Conference: News Media Center Room 211
|
|
|
|
|
|
|
|
- SWIFT Presentation Dr Saver: Hall D
|
|
|
|
|
|
|
|
900 Convention Center Blvd.
|
|
|
|
|
|
|
|
New Orleans
|
|
|
|
|
|
|
|
|
|
WHEN:
|
|
|
|
|
|
February 3, 2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- Press Conference at 8 AM CT
|
|
|
|
|
|
|
|
- SWIFT Presentation Dr Saver at 12 PM CT
|
|
|
|
|
|
|
|
|
ABOUT COVIDIEN
Covidien is a leading global healthcare products company that creates
innovative medical solutions for better patient outcomes and delivers
value through clinical leadership and excellence. Covidien manufactures,
distributes and services a diverse range of industry-leading product
lines in three segments: Medical Devices, Pharmaceuticals and Medical
Supplies. With 2011 revenue of $11.6 billion, Covidien has 41,000
employees worldwide in more than 65 countries, and its products are sold
in over 140 countries. Please visit www.covidien.com
to learn more about our business.
Source: Covidien
Covidien
Rachel Bloom Baglin, 508-452-6651
VP, Communications,
Vascular Therapies
cell: 774-284-1193
rachel.bloombaglin@covidien.com
or
David
T. Young, 508-452-1644
Manager, External Communications, Vascular
Therapies
cell: 774-284-2746
david.young@covidien.com
|
View printer-friendly version